Latest Board Appointments News

Western Yilgarn NL reports encouraging exploration results at its Ida Holmes Project, alongside a successful capital raising and strategic board changes, setting the stage for accelerated development in 2025.

Locksley Resources reports standout assay results from its Mojave Project alongside strategic board appointments and a comprehensive review of its Tottenham Copper Project, setting the stage for accelerated exploration and resource development.

DMC Mining Limited moves closer to ASX re-admission as Guinea reopens its cadastral licensing system, enabling imminent exploration licenses for key projects. The company also strengthens its leadership team and secures additional financing to support upcoming operations.

dorsaVi reported a modest 1.9% rise in sales revenue to $330k in Q2 FY25, launched its AI-powered Video AI movement analysis platform, and initiated a blockchain integration partnership to enhance data security.

Race Oncology has advanced its Phase 1 clinical trial for RC220, submitting ethics approvals and bolstering its cash reserves to $18.78 million following a $5.25 million R&D tax incentive.

Norwood Systems has launched its CogVoice OpenSpan platform on Microsoft Azure, deepening global CSP engagements and securing additional funding to support its AI-driven voice technology expansion.

Dragon Mountain Gold Limited reports promising drilling results at its Avalon Project and prepares for further exploration at Cawse, supported by a successful $670,000 capital raise and strategic board appointment.

Lycaon Resources completes its first drilling program at the Stansmore Nb-REE target, revealing modest mineralization, while reinforcing its leadership with key board appointments and planned capital injections.

Coppermoly Limited has advanced its Mt Isa exploration program with fresh geophysical surveys and strategic board appointments, aiming to unlock new copper and gold targets in Queensland.

Cycliq Group Ltd reports a robust Q2 FY2025 with a 15% rise in cash receipts to $1.92 million and strategic leadership appointments aimed at accelerating growth.

Argenica Therapeutics has dosed 80% of patients in its Phase 2 stroke trial and gained FDA orphan drug designations for its second candidate, ARG-006. The company reports a cash-positive quarter with $15 million in reserves.

Pioneer Lithium's Q4 2024 report highlights promising high-grade lithium assays at Root Lake, a key board appointment, and entry into Ontario's Junior Explorers Program, setting the stage for accelerated exploration.